Overview

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
0
Participant gender:
All
Summary
The goal of this clinical research study is to see if Gleevec, known as imatinib mesylate (STI571), can improve the disease condition in patients with hypereosinophilic syndrome, polycythemia vera, atypical CML or CMML with PDGF-R fusion genes, or mastocytosis.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Novartis Pharmaceuticals
Treatments:
Imatinib Mesylate
Criteria
Inclusion Criteria:

1. Pts must have 1 of the following hematopoietic malignancies: Hypereosinophilic
syndrome (HES), Polycythemia vera (PV), Atypical CML or CMML with PDGF-R fusion genes,
Mastocytosis, Serum bilirubin less than 2 mg%, serum creatinine less than 2 mg% unless
abnormality is considered due to hematologic malignancy by investigator, Eastern
Cooperative Oncology Group (ECOG) performance status < 3, life expectancy > 12 wks,

2. continued from above. Pts must sign informed consent indicating they are aware of the
investigational nature of the study, in keeping with policies of the hospital, women
of pregnancy potential must practice birth control. Women and men must continue birth
control for the duration of the trial and at least 3 months after the last dose of
study drug. Inclusion of women and minorities: As per NIH policy, women and members of
minorities will be included in this protocol as they are referred in the relevant
populations.

3. continued from above. There are no exclusions of women or minorities based on the
study objectives, New York Heart Association (NYHA) Class <3.

Exclusion Criteria:

N/A